Overview
The NCI’s Cancer Diagnosis Program in the Division of Cancer Treatment and Diagnosis is hosting a workshop on circulating tumor DNA (ctDNA) in cancer treatment and clinical care.
Previously, a workshop was held in 2016focused on promoting the translation of ctDNA assays into clinical research. In the intervening years, much progress has been made in the fast-evolving field of ctDNA, and clinical utility has been demonstrated.
There is now a need to establish guidelines to encourage standardization within different use cases in the broad spectrum of ctDNA applications, to facilitate study comparison and accelerate clinical validation and regulatory approval.
This meeting will gather members of the scientific community to discuss the current landscape and requirements for the future of ctDNA in the treatment and management of solid tumors, and explore how the community can best assess the value of ctDNA technology. Workshop topics include:
- Statistician and patient perspectives on ctDNA
- ctDNA for management of solid tumors in the neoadjuvant and adjuvant settings
- ctDNA post-treatment and MRD surveillance of solid tumors
- ctDNA for treatment of metastatic solid tumors
- The challenges of ctDNA as a biomarker
- Applications beyond DNA mutations and blood
- Advances in technology, assays, and clinical translation
Sign up for the in-person workshop using the form on the Registration page. The event will also be livestreamed; you can sign up as a remote viewer here. Please note that although the registration page shows “Day 1 of 2,” signing up will allow you to access the livestream for both days of the workshop.